Form 8-K - Current report:
SEC Accession No. 0001193125-26-273405
Filing Date
2026-06-17
Accepted
2026-06-17 08:03:19
Documents
10
Period of Report
2026-06-17
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K ck0001540171-20260617.htm   iXBRL 8-K 46854
2 EX-99.1 ck0001540171-ex99_1.htm EX-99.1 21067
  Complete submission text file 0001193125-26-273405.txt   183584

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ck0001540171-20260617.xsd EX-101.SCH 26030
13 EXTRACTED XBRL INSTANCE DOCUMENT ck0001540171-20260617_htm.xml XML 4938
Mailing Address 105 W FIRST ST. BOSTON MA 02127
Business Address 105 W FIRST ST. BOSTON MA 02127 (206) 707-0340
Avalyn Pharma Inc. (Filer) CIK: 0001540171 (see all company filings)

EIN.: 452463191 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-43251 | Film No.: 261096637
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)